StreetInsider.com News Articles

Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference

Thu, 28 May 2026 16:20:00 -0400

SOMERVILLE, Mass., May 28, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) today announced that it intends to participate in the Goldman Sachs Global Healthcare Conference on Monday, June 8, 2026.

Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference

Thu, 28 May 2026 16:20:00 -0400

Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference

Thu, 28 May 2026 16:20:00 -0400

Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference

Thu, 28 May 2026 16:20:00 -0400

Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference

Thu, 28 May 2026 16:20:00 -0400

Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference

Thu, 28 May 2026 16:20:00 -0400

Generate Biomedicines (GENB) PT Raised to $22 at Morgan Stanley

Thu, 14 May 2026 08:52:55 -0400

Morgan Stanley analyst Sean Laaman raised the price target on Generate Biomedicines (NASDAQ: GENB) to $22.00 (from $20.00) while maintaining a Overweight rating.

Generate Biomedicines (GENB) PT Raised to $25 at H.C. Wainwright

Fri, 08 May 2026 07:00:35 -0400

H.C. Wainwright analyst Mitchell Kapoor raised the price target on Generate Biomedicines (NASDAQ: GENB) to $25.00 (from $16.00) while maintaining a Buy rating.

Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

Thu, 07 May 2026 06:16:00 -0400

SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance
Clinical trial sites activated for GB-4362 (MMAE neutralizer); first patient dosing is expected in mid-2026; program has received FDA Fast Track designation
First patient dosing is expected in the second half of 2026 for GB-5267 (MUC16 armored CAR T); developed in collaboration with Roswell Park Comprehensive Cancer Center
Approximately $516.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026

SOMERVILLE, Mass., May 7, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) ("Generate") today reported financial results for the first quarter ended March

Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

Thu, 07 May 2026 06:16:00 -0400

SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance
Clinical trial sites activated for GB-4362 (MMAE neutralizer); first patient dosing is expected in mid-2026; program has received FDA Fast Track designation
First patient dosing is expected in the second half of 2026 for GB-5267 (MUC16 armored CAR T); developed in collaboration with Roswell Park Comprehensive Cancer Center
Approximately $516.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026

SOMERVILLE, Mass., May 7, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) ("Generate") today reported financial results for the first quarter ended March

Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

Thu, 07 May 2026 06:16:00 -0400

SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance
Clinical trial sites activated for GB-4362 (MMAE neutralizer); first patient dosing is expected in mid-2026; program has received FDA Fast Track designation
First patient dosing is expected in the second half of 2026 for GB-5267 (MUC16 armored CAR T); developed in collaboration with Roswell Park Comprehensive Cancer Center
Approximately $516.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026

SOMERVILLE, Mass., May 7, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) ("Generate") today reported financial results for the first quarter ended March

Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

Thu, 07 May 2026 06:16:00 -0400

SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance
Clinical trial sites activated for GB-4362 (MMAE neutralizer); first patient dosing is expected in mid-2026; program has received FDA Fast Track designation
First patient dosing is expected in the second half of 2026 for GB-5267 (MUC16 armored CAR T); developed in collaboration with Roswell Park Comprehensive Cancer Center
Approximately $516.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026

SOMERVILLE, Mass., May 7, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) ("Generate") today reported financial results for the first quarter ended March

Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

Thu, 07 May 2026 06:16:00 -0400

SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance
Clinical trial sites activated for GB-4362 (MMAE neutralizer); first patient dosing is expected in mid-2026; program has received FDA Fast Track designation
First patient dosing is expected in the second half of 2026 for GB-5267 (MUC16 armored CAR T); developed in collaboration with Roswell Park Comprehensive Cancer Center
Approximately $516.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026

SOMERVILLE, Mass., May 7, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) ("Generate") today reported financial results for the first quarter ended March

Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

Thu, 07 May 2026 06:16:00 -0400

SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance
Clinical trial sites activated for GB-4362 (MMAE neutralizer); first patient dosing is expected in mid-2026; program has received FDA Fast Track designation
First patient dosing is expected in the second half of 2026 for GB-5267 (MUC16 armored CAR T); developed in collaboration with Roswell Park Comprehensive Cancer Center
Approximately $516.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026

SOMERVILLE, Mass., May 7, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) ("Generate") today reported financial results for the first quarter ended March

H.C. Wainwright Starts Generate Biomedicines (GENB) at Buy

Mon, 13 Apr 2026 06:13:58 -0400

H.C. Wainwright initiates coverage on Generate Biomedicines (NASDAQ: GENB) with a Buy rating and a price target of $16.00.

For an analyst ratings summary and ratings history on Generate Biomedicines click here. For more ratings news on Generate Biomedicines click here.

Shares of Generate Biomedicines closed at $11.41 yesterday.

Generate Biomedicines (GENB) Reiterated at Overweight by Cantor Fitzgerald

Thu, 02 Apr 2026 08:02:12 -0400

Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Generate Biomedicines (NASDAQ: GENB).

The analyst commented, "We have updated our model to better reflect weighted average shares outstanding, resulting in changes to our EPS estimates from 2026 onward. There is no impact to our valuation."

For an analyst ratings summary and ratings history on Generate Biomedicines click here. For more ratings news on Generate Biomedicines click here.

Shares of Generate Biomedicines closed at $13.31 yesterday.

Cantor Fitzgerald Starts Generate Biomedicines (GENB) at Overweight

Tue, 24 Mar 2026 06:07:47 -0400

Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Generate Biomedicines (NASDAQ: GENB) with a Overweight rating.

For an analyst ratings summary and ratings history on Generate Biomedicines click here. For more ratings news on Generate Biomedicines click here.

Shares of Generate Biomedicines closed at $12.52 yesterday.

Piper Sandler Starts Generate Biomedicines (GENB) at Overweight

Tue, 24 Mar 2026 03:59:05 -0400

Piper Sandler analyst Edward Tenthoff initiates coverage on Generate Biomedicines (NASDAQ: GENB) with a Overweight rating and a price target of $24.00.

The analyst comments: "We are initiating coverage of Generate:Bomedicines with an Overweight rating and $24 price target. The Generate Platform is a protein discovery engine that integrates powerful AI/ML algorithms with high speed protein synthesis and multiplexed assays to design and validate novel therapeutics. Generate’s potential best-in-class anti-TSLP antibody GB-0895 is currently in two Phase III SOLAIRIA trials in severe asthma, and will report 6-month Phase Ib COPD data in 2Q:26. Additionally, Generate is preparing to start Phase I

Piper Sandler Starts Generate Biomedicines (GENB) at Overweight

Tue, 24 Mar 2026 03:59:05 -0400

Piper Sandler analyst Edward Tenthoff initiates coverage on Generate Biomedicines (NASDAQ: GENB) with a Overweight rating and a price target of $24.00.

Morgan Stanley Starts Generate Biomedicines (GENB) at Overweight

Tue, 24 Mar 2026 03:35:54 -0400

Morgan Stanley analyst Sean Laaman initiates coverage on Generate Biomedicines (NASDAQ: GENB) with a Overweight rating and a price target of $20.00.

The analyst comments: "We initiate coverage of Generate Biomedicines with an Overweight rating and a $20 price target. Our investment case is centered on GB-0895, an AI-engineered, long-acting anti-TSLP monoclonal antibody in Phase 3 for severe asthma with a parallel development path in COPD, and supported by two emerging oncology programs, GB-4362 and GB-5267. Together, these assets provide early but potentially compelling validation of the company’s AI-first discovery platform.

GB-0895 as a Best-in-Class, Long-Acting Anti-TSLP in Asthma. We believe GB-0895

Morgan Stanley Starts Generate Biomedicines (GENB) at Overweight

Tue, 24 Mar 2026 03:35:54 -0400

Morgan Stanley analyst Sean Laaman initiates coverage on Generate Biomedicines (NASDAQ: GENB) with a Overweight rating and a price target of $20.00.

GB-0895 as a Best-in-Class, Long-Acting Anti-TSLP in Asthma. We believe GB-0895

Goldman Sachs Starts Generate Biomedicines (GENB) at Buy

Tue, 24 Mar 2026 02:31:28 -0400

Goldman Sachs analyst Salveen Richter initiates coverage on Generate Biomedicines (NASDAQ: GENB) with a Buy rating and a price target of $26.00.

The analyst comments: "GENB is a clinical-stage biotechnology company integrating generative AI models with in-house experimental validation via its Generate Platform to produce optimized protein therapeutics. Lead asset, TSLP-targeting antibody GB-0895 ($7bn peak GSe global sales), improves 20x on AZN/AMGN's monthly Tezspire's binding affinity, enabling biannual dosing. We believe the Ph3 severe asthma data around early-29 will be in-line to Tezspire - the extended dosing will result in market share per KOL feedback and market analogues (e.g., psoriasis). Further,

Goldman Sachs Starts Generate Biomedicines (GENB) at Buy

Tue, 24 Mar 2026 02:31:28 -0400

Goldman Sachs analyst Salveen Richter initiates coverage on Generate Biomedicines (NASDAQ: GENB) with a Buy rating and a price target of $26.00.

Guggenheim Starts Generate Biomedicines (GENB) at Buy

Tue, 24 Mar 2026 01:51:03 -0400

Guggenheim analyst Seamus Fernandez initiates coverage on Generate Biomedicines (NASDAQ: GENB) with a Buy rating and a price target of $30.00.

The analyst comments: "We are initiating coverage of Generate:Biomedicines (GENB) with a BUY rating and $30/share price target based on our high conviction in multi-blockbuster sales for GENB's Phase 3 long-acting TSLP and the potential of an innovative, clinical-stage pipeline produced by the company's fully AI-integrated drug discovery engine. Critical to our thesis is GB-0895, the most advanced next-gen TSLP (to our knowledge), dosed every six months for what we estimate to be a $40B+ asthma and COPD market opportunity,

Guggenheim Starts Generate Biomedicines (GENB) at Buy

Tue, 24 Mar 2026 01:51:03 -0400

Guggenheim analyst Seamus Fernandez initiates coverage on Generate Biomedicines (NASDAQ: GENB) with a Buy rating and a price target of $30.00.